Literature DB >> 21444716

Signal- and development-dependent alternative splicing of LEF1 in T cells is controlled by CELF2.

Michael J Mallory1, Jason Jackson, Brittany Weber, Anthony Chi, Florian Heyd, Kristen W Lynch.   

Abstract

The HMG-box transcription factor LEF1 controls many developmentally regulated genes, including genes that activate expression of the T-cell antigen receptor alpha chain (TCR-alpha) in developing thymocytes. At least two distinct isoforms of LEF1 are expressed, resulting from variable inclusion of LEF1 exon 6; however, the expression pattern of these isoforms and mechanism of splicing regulation have not been explored. Here we demonstrate that inclusion of LEF1 exon 6 is increased during thymic development and in response to signaling in a cultured T-cell line in a manner which temporally correlates with increased expression of TCR-alpha. We further find that inclusion of exon 6 is dependent on the signal-induced increase in expression and binding of the splicing factor CELF2 to two intronic sequences flanking the regulated exon. Importantly, loss of exon 6 inclusion, through knockdown of CELF2 or direct block of the exon 6 splice site, results in reduced expression of TCR-alpha mRNA. Together, these data establish the mechanistic basis of LEF1 splicing regulation and demonstrate that LEF1 alternative splicing is a contributing determinant in the optimal expression of the TCR-alpha chain.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21444716      PMCID: PMC3133246          DOI: 10.1128/MCB.05170-11

Source DB:  PubMed          Journal:  Mol Cell Biol        ISSN: 0270-7306            Impact factor:   4.272


  40 in total

1.  Differential expression of CD45 isoforms is controlled by the combined activity of basal and inducible splicing-regulatory elements in each of the variable exons.

Authors:  Alan Tong; Jason Nguyen; Kristen W Lynch
Journal:  J Biol Chem       Date:  2005-09-19       Impact factor: 5.157

2.  Combinatorial control of signal-induced exon repression by hnRNP L and PSF.

Authors:  Alexis A Melton; Jason Jackson; Jiarong Wang; Kristen W Lynch
Journal:  Mol Cell Biol       Date:  2007-07-30       Impact factor: 4.272

3.  The beta-catenin/T-cell factor/lymphocyte enhancer factor signaling pathway is required for normal and stress-induced cardiac hypertrophy.

Authors:  Xin Chen; Sergei P Shevtsov; Eileen Hsich; Lei Cui; Syed Haq; Mark Aronovitz; Risto Kerkelä; Jeffery D Molkentin; Ronglih Liao; Robert N Salomon; Richard Patten; Thomas Force
Journal:  Mol Cell Biol       Date:  2006-06       Impact factor: 4.272

4.  HnRNP L represses exon splicing via a regulated exonic splicing silencer.

Authors:  Caryn R Rothrock; Amy E House; Kristen W Lynch
Journal:  EMBO J       Date:  2005-07-07       Impact factor: 11.598

Review 5.  Diversity of LEF/TCF action in development and disease.

Authors:  L Arce; N N Yokoyama; M L Waterman
Journal:  Oncogene       Date:  2006-12-04       Impact factor: 9.867

6.  Tissue-specific and cell type-specific RNA interference in vivo.

Authors:  Manjeet K Rao; Miles F Wilkinson
Journal:  Nat Protoc       Date:  2006       Impact factor: 13.491

7.  Global analysis of alternative splicing during T-cell activation.

Authors:  Joanna Y Ip; Alan Tong; Qun Pan; Justin D Topp; Benjamin J Blencowe; Kristen W Lynch
Journal:  RNA       Date:  2007-02-16       Impact factor: 4.942

8.  ETR-3 represses Tau exons 2/3 inclusion, a splicing event abnormally enhanced in myotonic dystrophy type I.

Authors:  Olivier Leroy; Claire-Marie Dhaenens; Suzanna Schraen-Maschke; Karim Belarbi; André Delacourte; Athena Andreadis; Bernard Sablonnière; Luc Buée; Nicolas Sergeant; Marie-Laure Caillet-Boudin
Journal:  J Neurosci Res       Date:  2006-09       Impact factor: 4.164

9.  Depolarization and CaM kinase IV modulate NMDA receptor splicing through two essential RNA elements.

Authors:  Ji-Ann Lee; Yi Xing; David Nguyen; Jiuyong Xie; Christopher J Lee; Douglas L Black
Journal:  PLoS Biol       Date:  2007-02       Impact factor: 8.029

10.  Exon silencing by UAGG motifs in response to neuronal excitation.

Authors:  Ping An; Paula J Grabowski
Journal:  PLoS Biol       Date:  2007-02       Impact factor: 8.029

View more
  33 in total

Review 1.  Cell-context dependent TCF/LEF expression and function: alternative tales of repression, de-repression and activation potentials.

Authors:  Catherine D Mao; Stephen W Byers
Journal:  Crit Rev Eukaryot Gene Expr       Date:  2011       Impact factor: 1.807

2.  Alternative splicing networks regulated by signaling in human T cells.

Authors:  Nicole M Martinez; Qun Pan; Brian S Cole; Christopher A Yarosh; Grace A Babcock; Florian Heyd; William Zhu; Sandya Ajith; Benjamin J Blencowe; Kristen W Lynch
Journal:  RNA       Date:  2012-03-27       Impact factor: 4.942

Review 3.  Recent insights into the transcriptional control of the Tcra/Tcrd locus by distant enhancers during the development of T-lymphocytes.

Authors:  Cristina Hernández-Munain
Journal:  Transcription       Date:  2015

4.  PSF controls expression of histone variants and cellular viability in thymocytes.

Authors:  Florian Heyd; Kristen W Lynch
Journal:  Biochem Biophys Res Commun       Date:  2011-10-06       Impact factor: 3.575

5.  Induced transcription and stability of CELF2 mRNA drives widespread alternative splicing during T-cell signaling.

Authors:  Michael J Mallory; Samuel J Allon; Jinsong Qiu; Matthew R Gazzara; Iulia Tapescu; Nicole M Martinez; Xiang-Dong Fu; Kristen W Lynch
Journal:  Proc Natl Acad Sci U S A       Date:  2015-04-13       Impact factor: 11.205

6.  T-cell receptor α enhancer is inactivated in αβ T lymphocytes.

Authors:  Beatriz del Blanco; Úrsula Angulo; Michael S Krangel; Cristina Hernández-Munain
Journal:  Proc Natl Acad Sci U S A       Date:  2015-03-23       Impact factor: 11.205

7.  Activation-Dependent TRAF3 Exon 8 Alternative Splicing Is Controlled by CELF2 and hnRNP C Binding to an Upstream Intronic Element.

Authors:  Astrid-Solveig Schultz; Marco Preussner; Mario Bunse; Rotem Karni; Florian Heyd
Journal:  Mol Cell Biol       Date:  2017-03-17       Impact factor: 4.272

8.  Convergence of Acquired Mutations and Alternative Splicing of CD19 Enables Resistance to CART-19 Immunotherapy.

Authors:  Elena Sotillo; David M Barrett; Kathryn L Black; Asen Bagashev; Derek Oldridge; Glendon Wu; Robyn Sussman; Claudia Lanauze; Marco Ruella; Matthew R Gazzara; Nicole M Martinez; Colleen T Harrington; Elaine Y Chung; Jessica Perazzelli; Ted J Hofmann; Shannon L Maude; Pichai Raman; Alejandro Barrera; Saar Gill; Simon F Lacey; Jan J Melenhorst; David Allman; Elad Jacoby; Terry Fry; Crystal Mackall; Yoseph Barash; Kristen W Lynch; John M Maris; Stephan A Grupp; Andrei Thomas-Tikhonenko
Journal:  Cancer Discov       Date:  2015-10-29       Impact factor: 39.397

Review 9.  Post-transcriptional coordination of immunological responses by RNA-binding proteins.

Authors:  Panagiota Kafasla; Antonis Skliris; Dimitris L Kontoyiannis
Journal:  Nat Immunol       Date:  2014-06       Impact factor: 25.606

10.  Integrated molecular analysis of adult T cell leukemia/lymphoma.

Authors:  Keisuke Kataoka; Yasunobu Nagata; Akira Kitanaka; Yuichi Shiraishi; Teppei Shimamura; Jun-Ichirou Yasunaga; Yasushi Totoki; Kenichi Chiba; Aiko Sato-Otsubo; Genta Nagae; Ryohei Ishii; Satsuki Muto; Shinichi Kotani; Yosaku Watatani; June Takeda; Masashi Sanada; Hiroko Tanaka; Hiromichi Suzuki; Yusuke Sato; Yusuke Shiozawa; Tetsuichi Yoshizato; Kenichi Yoshida; Hideki Makishima; Masako Iwanaga; Guangyong Ma; Kisato Nosaka; Masakatsu Hishizawa; Hidehiro Itonaga; Yoshitaka Imaizumi; Wataru Munakata; Hideaki Ogasawara; Toshitaka Sato; Ken Sasai; Kenzo Muramoto; Marina Penova; Takahisa Kawaguchi; Hiromi Nakamura; Natsuko Hama; Kotaro Shide; Yoko Kubuki; Tomonori Hidaka; Takuro Kameda; Tsuyoshi Nakamaki; Ken Ishiyama; Shuichi Miyawaki; Sung-Soo Yoon; Kensei Tobinai; Yasushi Miyazaki; Akifumi Takaori-Kondo; Fumihiko Matsuda; Kengo Takeuchi; Osamu Nureki; Hiroyuki Aburatani; Toshiki Watanabe; Tatsuhiro Shibata; Masao Matsuoka; Satoru Miyano; Kazuya Shimoda; Seishi Ogawa
Journal:  Nat Genet       Date:  2015-10-05       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.